Table 1.
Characteristics of Participants with Non-anergic DTH Test Results at the Time of Last HBV Vaccination by Vaccine Response Category
| Characteristic | N | Anti-HBs < 10 IU/L N = 221 |
Anti-HBs ≥ 10 IU/L N = 148 |
P |
|---|---|---|---|---|
|
| ||||
| Age (years) | 369 | 31 (27–36) | 31 (26–37) | 0.76 |
|
| ||||
| Gender, Male | 369 | 202 (91) | 124 (84) | 0.03 |
|
| ||||
| Ethnicity | 369 | 0.85 | ||
| Caucasian | 96 (43) | 59 (40) | ||
| African American | 98 (44) | 66 (45) | ||
| Other | 27 (12) | 23 (16) | ||
|
| ||||
| CD4 Count (cells/uL) | 360 | 451 (318–613) | 573 (418–737) | <0.001 |
|
| ||||
| CD4 Count Category (cells/uL) | 360 | <0.001 | ||
| <200 | 23 (10) | 6 (4) | ||
| 200–499 | 103 (47) | 49 (33) | ||
| ≥500 | 90 (41) | 89 (60) | ||
|
| ||||
| HIV VL (log10 copies/mL) | 231 | 3.33 (2.30–4.38) | 2.30 (2.21–3.85) | <0.001 |
|
| ||||
| HIV VL category (copies/mL) | 369 | <0.001 | ||
| ≤400 | 37 (17) | 46 (31) | ||
| >400 | 85 (38) | 63 (43) | ||
| Unknown | 99 (45) | 39 (26) | ||
|
| ||||
| Number of Vaccinations | 369 | 0.09 | ||
| 1–2 | 102 (46) | 55 (37) | ||
| ≥3 | 119 (54) | 93 (63) | ||
|
| ||||
| On ART at Vaccination | 369 | 182 (82) | 102 (69) | <0.01 |
|
| ||||
| Year of Vaccination | 369 | <0.001 | ||
| <1996 | 134 (61) | 58 (39) | ||
| ≥1996 | 87 (39) | 90 (61) | ||
|
| ||||
| Follow-up (years) | 369 | 5.4 (2.5–10.1) | 6.7 (3.0–11.2) | 0.16 |
| Total (patient-years) | 1,463 | 1,071 | ||
|
| ||||
| Total Number of AIDS or Death Events | 369 | 68 | 17 | <0.001 |
DTH, delayed-type hypersensitivity; HBV, hepatitis B virus; anti-HBs, antibody to HBV surface antigen; VL, viral load; ART, antiretroviral therapy
Data are number (%) or median (interquartile range) unless otherwise specified